Cancer drug development with the help of radiopharmaceuticals: Academic experience

Current Pharmaceutical Design

Volumn 15, Issue 9, 2009, Pages 950-956

  Larson, Steven M ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Nuclear Medicine Service   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE F 18; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CYTOTOXIC AGENT; DASATINIB F 18; FLUORODEOXYGLUCOSE F 18; FOLIC ACID ANTAGONIST; INDIUM 111; MONOCLONAL ANTIBODY G250; MONOCLONAL ANTIBODY MORAB 003; NANOCARRIER; PROTEIN TYROSINE KINASE; QUINAZOLINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; DRUG CARRIER; NANOPARTICLE; RADIOISOTOPE;

CLEAR CELL CARCINOMA; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG MONITORING; DRUG PENETRATION; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; DRUG TUMOR LEVEL; HUMAN; ISOTOPE LABELING; KIDNEY CARCINOMA; MOLECULAR IMAGING; NONHUMAN; OVARY CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOLID TUMOR; TREATMENT RESPONSE; ANIMAL; BIOAVAILABILITY; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG DESIGN; METHODOLOGY; NEOPLASM; SCINTISCANNING;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; NANOPARTICLES; NEOPLASMS; RADIOISOTOPES; RADIOPHARMACEUTICALS;

EID: 65549108376     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209787581959     Document Type: Review

References (59)

1. Halldin C, Gulyas B, Farde L. PET for drug development: Ernst Schering Res Found Workshop 2004; 95-109.
2. Halldin C, Gulyas B, Farde L. PET studies with carbon-11 radioligands in neuropsychopharmacological drug development. Curr Pharm Des 2001; 7: 1907-29.
3. O'Connor JP, Jackson A, Asselin MC, Buckley DL, Parker GJ, Jayson GC. Quantitative imaging biomarkers in the clinical development of targeted therapeutics: current and future perspectives. Lancet Oncol 2008; 9: 766-76.
4. Willmann JK, van Bruggen N, Dinkelborg LM, Gambhir SS. Molecular imaging in drug development. Nat Rev Drug Discov 2008; 7:591-607.
5. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
6. Simpson AJ, Caballero OL, Jungbluth A, Chen Y T, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005; 5: 615-25.
7. Croce CM. Oncogenes and cancer. N Engl J Med 2008; 358: 502-11.
8. Gomase VS, Tagore S, Kale KV, Bhiwgade DA. Oncogenomics. Curr Drug Metab 2008; 9: 199-206.
9. Sharma SV, Settleman J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev 2007; 21: 3214-31.
10. Risch A, Plass C. Lung cancer epigenetic and genetics. Int J Cancer 2008; 123: 1-7.
11. Larson SM, Schoder H. Advances in positron emission tomography applications for urologic cancers. Curr Opin Urol 2008; 18: 65-70.
12. Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov 2003; 2: 566-80.
13. Hargreaves RJ. The role of molecular imaging in drug discovery and development. Clin Pharmacol Ther 2008; 83: 349-53.
14. Yu EY, Mankoff DA. Positron emission tomography imaging as a cancer biomarker. Expert Rev Mol Diagn 2007; 7: 659-72.
15. Deberardinis RJ, Sayed N, Ditsworth D, Thompson CB. Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev 2008; 18: 54-61.
16. Ortega AD, Sanchez-Arago M, Giner-Sanchez D, Sanchez-Cenizo L, Willers I, Cuezva JM. Glucose avidity of carcinomas. Cancer Lett 2008; [Epub ahead of print].
17. Downey RJ, Akhurst T, Gonen M, Vincent A, Bains MS, Larson S, et al. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol 2004; 22: 3255-60.
18. Rizk N, Downey RJ, Akhurst T, Gonen M, Bains MS, Larson S, et al. Preoperative 18[F]-fluorodeoxyglucose positron emission tomography standardized uptake values predict survival after esophageal adenocarcinoma resection. Ann Thorac Surg 2006; 81: 1076-81.
19. Sgouros U, Kolbert KS, Sheikh A, Pentlow KS, Mun EF, Barth A, et al. Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med 2004; 45: 1366-72.
20. Schoder H, Noy A, Gonen M, Weng L, Green D, Erdi YE, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 4643-51.
21. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol1 993; 11: 2101-11.
22. Downey RJ, Akhurst T, Ilson D, Ginsberg R, Bains MS, Gonen M, et al. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol 2003; 21: 428-32.
23. Larson SM, Morris M, Gunther I, Beattie B, Humm JL, Akhurst TA, et al. Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med 2004; 45: 366-73.
24. Juweid ME, Wiseman GA, Vose JM, Ritchie JM, Menda Y, Wooldridge JE, et al. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 2005; 23: 4652-61.
25. Schwaiger M, Wieder H. Role of PET in lymphoma. Chang Gung Med J 2005; 28: 315-25.
26. Alonso A, Molenberghs G, Geys H, Buyse M, Vangeneugden T. A unifying approach for surrogate marker validation based on Prentice's criteria. Stat Med 2006; 25: 205-21.
27. Blay JY, Bonvalot S, Casali P, Choi H, Debiec-Richter M, Dei Tos AP, et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 2005; 16: 566-78.
28. Van den Abbeele AD. The lessons of GIST-PET and PET/CT: a new paradigm for imaging. Oncologist 2008; 13(Suppl 2): 8-13.
29. Shields AF. PET imaging with 18F-FLT and thymidine analogs: promise and pitfalls. J Nucl Med 2003; 44: 1432-4.
30. Solit DB, Santos E, Pratilas CA, Lobo J, Moroz M, Cai S, et al. 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography is a sensitive method for imaging the response of BRAF-dependent tumors to MEK inhibition. Cancer Res 2007; 67: 11463-9.
31. Graf N, Herrmann K, den Hollander J, Fend F, Schuster T, Wester HJ, et al. Imaging proliferation to monitor early response of lymphoma to cytotoxic treatment. Mol Imaging Biol 2008; 10: 349-55.
32. Herrmann K, Wieder HA, Buck AK, Schoffel M, Krause BJ, Fend F, et al. Early response assessment using 3′-deoxy-3′-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma. Clin Cancer Res 2007; 113: 3552-8.
33. Dehdashti F, Picus J, Michalski JM, Dence CS, Siegel BA, Katzenellenbogen JA, et al. Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur J Nucl Med Mol Imaging 2005; 32: 344-50.
34. Dehdashti F, Mortimer JE, Trinkaus K, Naughton MJ, Ellis M, Katzenellenbogen JA, et al. PET-based estradiol challenge as a predictive biomarket of response to endocrine therapy in women with estrogen-receptor-positive breast cancer. Breast Cancer Res Treat 2008; [Epub ahead of print].
35. Mortimer JE, Dehdashti F, Siegel BA, Trinkaus K, Katzenellenbogen JA, Welch MJ. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol 2001; 19: 2797-803.
36. Smith-Jones PM, Pandit-Taskar N, Cao W, O'Donoghue J, Philips MD, Carrasquillo J, et al. Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003. Nucl Med Biol 2008; 35: 343-51.
37. Divgi CR, Pandit-Taskar N, Jungbluth AA, Reuter VE, Gonen M, Ruan S, et al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol 2007; 8: 304-10.
38. Pal A, Glekas A, Doubrovin M, Balatoni J, Namavari M, Beresten T, et al. Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography. Mol Imaging Biol 2006; 8: 262-77.
39. Penate O, Pillarsetty N, Longo V, Punzala B, Zanzonico P, Smith-Jones P, et al. Tumor imaging using a combination of positron labeled EGFR tyrosine kinase inhibitors and stealth nanocarriers. SNM New Orleans. Mol Imaging Abstr Track #733 2008.
40. Reivich M, Kuhl D, Wolf A, Greenberg J, Phelps M, Ido T, et al. The [18F]fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man. Circ Res 1979; 44: 127-37.
41. Grierson JR, Shields AF. Radiosynthesis of 3′-deoxy:3′[(18)F]-fluorothymidine: [(18)F]FLT for imaging of cellular proliferation in vivo. Nucl Med Biol 2000; 27: 143-56.
42. Mankoff DA, Shields AF, Krohn KA. PET imaging of cellular proliferation. Radiol Clin North Am 2005; 43: 153-67.
43. Shields AF, Lawhorn-Crews JM, Briston DA, Zalzala S, Gadgeel S, Douglas KA, et al. Analysis and reproducibility of 3′-Deoxy-3′-[18F]fluorothymidine positron emission tomography imaging in patients with non-small cell lung cancer. Clin Cancer Res 2008; 14: 4463-8.
44. Langstrom B, Lundqvist H. The preparation of 11C-methyl iodide and its use in the synthesis of 11C-methyl-L-methionine. Int J Appl Radiat Isot 1976; 27: 357-63.
45. Lilja A, Lundqvist H, Olsson Y, Spannare B, Gullberg P, Langstrom B. Positron emission tomography and computed tomography in differential diagnosis between recurrent or residual glioma and treatment-induced brain lesions. Acta Radiol 1989; 30: 121-8.
46. Nye JA, Schuster DM, Yu W, Camp VM, Goodman MM, Votaw JR. Biodistribution and radiation dosimetry of the synthetic nonmetabolized amino acid analogue anti-18F-FACBC in humans. J Nucl Med 2007; 48: 1017-20.
47. Shoup TM, Olson J, Hoffman JM, Votaw J, Eshima D, Eshima L, et al. Synthesis and evaluation of [18F]1-amino-3-fluorocyclobutane-1-carboxylic acid to image brain tumors. J Nucl Med 1999; 40: 331-8.
48. VanBrocklin HF, Carlson KE, Katzenellenbogen JA, Welch MJ. 16 beta-([18F]fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors. J Med Chem 1993; 36: 1619-29.
49. No-pasera. TA, O'Neil JP, Xu M, Dobkin JA, Cutler PD, Lich LL, et al. Preclinical evaluation of fluorine-18-labeled androgen receptor ligands in baboons. J Nucl Med 1996; 3 7: 1009-15.
50. Schoder H, Larson SM. Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med 2004; 34: 274-92.
51. Rasey JS, Grunbaum Z, Magee S, Nelson NJ, Olive PL, Durand RE, et al. Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells. Radiat Res 1987; 111: 292-304.
52. Rasey JS, Koh WJ, Grierson JR, Grunbaum Z, Krohn KA. Radiolabelled fluoromisonidazole as an imaging agent for tumor hypoxia. Int J Radiat Oncol Biol Phys 1989; 17: 985-91.
53. Nehmeh SA, Lee NY, Schroder H, Squire O, Zanzonico PB, Erdi YE, et al. Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys 2008; 70: 235-42.
54. Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Larson SM. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 2004; 22: 701-6.
55. Larson SM, Pentlow KS, Volkow ND, Wolf AP, Finn RD, Lambrecht RM, et al. PET scanning of iodine-124-3F9 as an approach to tumor dosimetry during treatment planning for radioimmunotherapy in a child with neuroblastoma. J Nucl Med 1992; 33: 2020-3.
56. Jaggi JS, Carrasquillo JA, Seshan SV, Zanzonico P, Henke E, Nagel A, et al. mproved tumor imaging and therapy via ix. IgG-mediated time-sequential modulation of neonatal Fc receptor. J Clin Invest 2007; 117: 2422-30.
57. Berginann-Leitner E. Anti-cancer drugs. Curr Pharm Des 2008; 14(11): 1048.
58. Chikuma M, Sato T, Komeda S. Current status of and future perspectives for platinum antitumor drugs. Yakugaku Zasshi 2008; 128(3): 307-16.
59. Spankuch B, Strebhardt K. Combinatorial application of nucleic acid-based agents targeting protein kinases for cancer treatment. Curr Pharm Des 2008; 14(11): 1098-112.